ID: h-84566f4d8e
Hypothesis

Perturbation-first validation should precede therapeutic claims for Causal Sequence of TDP-43 Nuclear Clearance to Cytoplasmic Aggregation in ALS Motor Neurons

The debate supports treating this as a validation program before ranking it as a therapy.
🩺 neurodegeneration🎯 Composite 61%💱 $0.56▼8.4%proposed
EvidencePending (0%)📖 0 cit🗣 1 debates 1 support 1 oppose
⚠ Missing Evidence⚠ No Target Gene Senate Quality Gates →
Mechanistic 0.63 (15%) Evidence 0.55 (15%) Novelty 0.60 (12%) Feasibility 0.76 (12%) Impact 0.57 (12%) Druggability 0.48 (10%) Safety 0.60 (8%) Competition 0.55 (6%) Data Avail. 0.68 (5%) Reproducible 0.66 (5%) KG Connect 0.50 (8%) 0.608 composite

🧪 Overview

The debate supports treating this as a validation program before ranking it as a therapy. Perturbation should move a proximal molecular phenotype, then a disease-relevant phenotype, in that order.

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

flowchart TD
    A["TDP-43 Nuclear Clearance Cascade<br/>ALS Motor Neuron Degeneration Mechanism"]
    B["Perturbation-First Validation Required<br/>Confirm Causal Sequence"]
    C["TDP-43 Restoration Strategies<br/>AAV9, antisense oligonucleotides, small molecules"]
    D["Motor Neuron Function Recovery<br/>Electrophysiology and Survival Assays"]
    E["Cryptic Exon Splicing Reversal<br/>STMN2, UNC13A Normalization"]
    F["ALS Therapeutic Candidate<br/>TDP-43 Clearance Prevention Evidence"]
    A --> B
    B --> C
    C --> D
    D --> E
    E --> F
    style A fill:#4a148c,stroke:#ce93d8,color:#ce93d8
    style F fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a

⚖️ Evidence

⚖️ Evidence Matrix1 supports1 contradicts
Supports
The proposed priority experiment is concrete: time-resolved iPSC motor-neuron perturbations combining RNA stoichiometry, PTM mapping, live-cell condensate tracking, and cryo-electron tomography
Contradicts
Therapeutic tractability is not established by the current source evidence.
📖 Linked Papers

No linked papers recorded for this hypothesis yet.

🏥 Translation

💉 Clinical Trials

No clinical trials data linked to this hypothesis yet.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

No DepMap CRISPR Chronos data found for this gene.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Stable
7d Momentum
▼ 0.7%
Volatility
Low
0.0016
Events (7d)
3
Price History
▼8.4%

💾 Resource Usage

No resource usage or linked notebooks recorded for this hypothesis yet.

Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
sourcev1_phase_c_backfill
origin_typedebate_synthesizer
_schema_version1
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting 0 contradicting 0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.